Rapamycin passes the torch: a new generation of mTOR inhibitors

  title={Rapamycin passes the torch: a new generation of mTOR inhibitors},
  author={Don Benjamin and Marco Colombi and Christoph Moroni and Michael N. Hall},
  journal={Nature Reviews Drug Discovery},
Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metabolism in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders. Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999. In recent years, interest has focused on its potential as an anticancer drug. However, the performance of rapamycin and its analogues (rapalogues) has been… 

Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents

Key preclinical and early clinical investigations of several catalytic mTOR inhibitors and potential resistance mechanisms to their activities are summarized here.

mTOR pathway in colorectal cancer: an update

The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition,

Revisiting mTOR inhibitors as anticancer agents.

The expanding role of mTOR in cancer cell growth and proliferation.

This work focuses on the signalling pathways that lie both upstream and downstream of mTORC1, as well as their relevance to human pathologies, and discusses pharmacological approaches that target mTOR and their applications for the treatment of cancer.

Research progress of mTOR inhibitors.

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer

The therapeutic potential of targeting the mTOR pathway for the treatment of several malignancies will reach a maximum point in the next few years and may ultimately change the way the authors treat several malignant tumors.

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment

This review provides insight into the binding of mTOR inhibitors with the ATP-binding site, and deduce that a hypothetical binding mode is from docking studies, co-crystal structures and the structure–activity relationships (SARs).

Adverse events associated with mTOR inhibitors

A comprehensive survey of the safety profiles of various rapalog-based therapies from the available clinical literature is performed to discuss the potential mechanisms of these therapies, taking into account the knowledge of the biological pathways regulated by mTOR.

Targeting the PI3K/Akt/mTOR Signaling Pathway: Applications of Nanotechnology

MTOR and its inhibitors including the rapamycin analogues are attractive therapeutic indication to clinical trials for treating various types of cancers, with or without inhibitors of other signaling pathways.



Rapamycin and mTOR kinase inhibitors

Further development of selective mTOR kinase inhibitors holds the promise of yielding potent anticancer drugs with a novel mechanism of action.

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Three pyrazolopyrimidine ATP-competitive mTOR inhibitors are reported, with significant selectivity over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold), to highlight mechanistic differentiation between rapalogs and mTOR kinase inhibitors in targeting cancer cell growth and survival and provide support for clinical development of mTORKinase inhibitors as new cancer therapy.

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

It is established that Ph+ transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

The results further validate mTOR as a critical driver for tumor growth, establish WYE-132 as a potent and profound anticancer agent, and provide a strong rationale for clinical development of specific mTOR kinase inhibitors as new cancer therapy.

Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review

This review focuses on ATP-competitive mTOR inhibitors that have appeared in the patent literature in 2010 and endeavors to put into perspective the diverse structural elements that make up these compounds.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

AZD8055 is described, a novel ATP-competitive inhibitor of mTOR kinase activity, with an IC50 of 0.8 nmol/L, which results in significant growth inhibition and/or regression in xenografts, representing a broad range of human tumor types.

TOR Signaling in Growth and Metabolism

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Mammalian Target of Rapamycin: Hitting the Bull's-Eye for Neurological Disorders

The role of mTOR and the downstream signaling pathways are significantly involved in the central nervous system (CNS) with synaptic plasticity, memory retention, neuroendocrine regulation associated with food intake and puberty and modulation of neuronal repair following injury.